SYS-CON MEDIA Authors: Carmen Gonzalez, Peter Silva, Kevin Jackson, Jessica Qiu, Dana Gardner

News Feed Item

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

NEW YORK, Feb. 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029815/PharmaPoint-Non-Small-Cell-Lung-Cancer---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets. However, while the US and Japanese markets will continue to grow, increasing cost pressures from European regulatory agencies will counteract these drivers in the EU markets.

Highlights

Key Questions Answered

- The NSCLC market will become increasingly crowded during the forecast. How will the first and second lines of therapy be impacted by the launch of new therapies?
- How will the increasing stratification of patient populations by biomarkers affect the treatment landscape?
- The unmet needs of NSCLC patients are relatively high. What unmet needs will be addressed by the launch of new treatment options during the forecast period? What unmet needs will remain?
- How will Alimta, Avastin, Iressa and Tarceva patent expirations affect overall market growth during the forecast?
- How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU?
- How will the difficult-to-penetrate Indian and Chinese NSCLC markets be affected by launch of pipeline candidates?/

Key Findings

- Launch of emerging pipeline therapies will result in more patients receiving premium-priced drugs in the first and second lines of therapy, and market growth in the US and Japan.
- Despite the launch of new premium-priced therapies and increasing incident cases, the NSCLC market will shrink in the 5EU. This will be primarily due to loss of patent protection for most of the major branded therapies as well as increasing cost pressures from European reimbursement authorities.
- The Indian and Chinese markets will continue to be difficult to penetrate. Many emerging pipeline therapies will not launch in these markets, especially expensive biologic therapies. Generic competition, regulatory hurdles and high cost of therapies will be major barriers to growth in these markets.
- BMS's nivolumab will emerge as the overall market leader in 2022, launching first in the second-line segment in 2016 and expanding into the first-line segment in 2019. Uptake will be driven by the drug's promising clinical efficacy in both squamous and non-squamous patients and strong safety profile.
- After Iressa and Tarceva lose patent protection in 2019 and 2020, respectively, Boehringer Ingelheim's afatinib will emerge as the leading therapy for EGFR-positive patients. Afatinib's market position will be driven by high uptake in the second-line segment.
- Pfizer's Xalkori will lose ALK-positive patient share to Novartis' LDK378 in the second-line segment. However, Xalkori will continue to be the patient share leader in the more lucrative first line setting and will maintain the overall sales leadership over LDK378 throughout the forecast.

Scope

- Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized NSCLC therapeutics market revenue, annual cost of therapy and treatment usage pattern data by patient segment forecast from 2012 to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the NSCLC therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising 13 candidates in Phase III development are profiled.
- Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NSCLC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Forecast drug sales in the global NSCLC therapeutics market from 2012-2022.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27

3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology and Histology 27
3.1.3 NSCLC Biomarkers 28
3.1.4 Quality of Life 29
3.2 Symptoms 30
4 Epidemiology 31
4.1 Risk Factors and Comorbidities 32
4.1.1 Smokers are more likely to have lung cancer than non-smokers 33
4.1.2 Long-term exposure to radon increases the risk of lung cancer 35
4.1.3 Family history of any cancer increases lung cancer risk 35
4.1.4 TB increases the risk of lung cancer and increases mortality risk 35
4.1.5 COPD is a comorbidity that reduces lung cancer survival 36
4.1.6 Lung cancer screening programs may not be beneficial 36
4.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 37
4.2 Global Trends 38
4.2.1 US 41
4.2.2 France 46
4.2.3 Germany 47
4.2.4 Italy 49
4.2.5 Spain 51
4.2.6 UK 53
4.2.7 Japan 54
4.2.8 China 56
4.2.9 India 58
4.3 Forecast Methodology 60
4.3.1 Sources Used 61
4.3.2 Sources Not Used 66
4.3.3 Forecast Assumptions and Methods 67
4.4 Epidemiology Forecast (2012-2022) 69
4.4.1 Incident/Prevalent Cases of NSCLC 69
4.4.2 Age-Specific Incident Cases of NSCLC 71

4.4.3 Sex-Specific Incident Cases of NSCLC 72
4.4.4 Age-Standardized Incidence Rates of NSCLC 74
4.4.5 Segmentation of NSCLC Incident Cases 75
4.5 Discussion 83
4.5.1 Limitations of the Analysis 84
4.5.2 Strengths of the Analysis 85
5 Disease Management 86
5.1 Treatment Overview 86
5.1.1 Diagnosis 87
5.1.2 Clinical Staging 88
5.1.3 Screening and Early Detection 89
5.1.4 Localized Procedures and Therapies 91
5.1.5 Systemic Chemotherapy 91
5.1.6 Targeted Therapy 92
5.2 US 94
5.2.1 Diagnosis 94
5.2.2 Clinical Practice 95
5.3 France 97
5.3.1 Diagnosis 97
5.3.2 Clinical Practice 98
5.4 Germany 99
5.4.1 Diagnosis 99
5.4.2 Clinical Practice 100
5.5 Italy 102
5.5.1 Diagnosis 102
5.5.2 Clinical Practice 102
5.6 Spain 103
5.6.1 Diagnosis 103
5.6.2 Clinical Practice 104
5.7 UK 105
5.7.1 Diagnosis 105
5.7.2 Clinical Practice 105
5.8 Japan 107
5.8.1 Diagnosis 107
5.8.2 Clinical Practice 107
5.9 China 109
5.9.1 Diagnosis 109
5.9.2 Clinical Practice 109

5.10 India 110
5.10.1 Diagnosis 110
5.10.2 Clinical Practice 111
6 Competitive Assessment 113
6.1 Overview 113
6.2 Strategic Competitor Assessment 114
6.3 Product Profiles - Major Brands, Chemotherapies 116
6.3.1 Alimta (pemetrexed disodium) 116
6.3.2 Abraxane (nab-paclitaxel) 121
6.4 Product Profiles - Major Brands, Targeted Therapies 125
6.4.1 Iressa (gefitinib) 125
6.4.2 Tarceva (erlotinib hydrochloride) 130
6.4.3 Xalkori (crizotinib) 136
6.4.4 Avastin (bevacizumab) 141
7 Opportunity and Unmet Need 145
7.1 Overview 145
7.2 Improved Overall Survival and Less Toxicity 147
7.3 Treatments for Patients with Acquired TKI Resistance 147
7.4 Better Treatment Options for Squamous Patients 148
7.5 Preventing Relapse or Recurrence 149
7.6 More Efficacious Second-Line Therapies 149
7.7 Increased Availability of Mutation Testing 150
7.8 More Cost-Effective Therapies 150
7.9 Unmet Needs Gap Analysis 151
8 Pipeline Assessment 154
8.1 Overview 154
8.2 Clinical Trial Mapping 155
8.2.1 Clinical Trials by Country 155
8.3 Clinical Trials by Phase and Trial Status 156
8.4 Promising Drugs in Clinical Development 157
8.4.1 onartuzumab (MetMab) 160
8.4.2 necitumumab (IMC-11F8) 167
8.4.3 ramucirumab (IMC-1121B) 173
8.4.4 custirsen (OGX-011) 178
8.4.5 ganetespib (STA-9090) 184
8.4.6 nintedanib (BIBF1120) 191
8.4.7 afatinib (BIBW-2992) 196

8.4.8 dacomitinib (PF-00299804) 202
8.4.9 LDK378 207
8.4.10 Yervoy (ipilimumab) 213
8.4.11 nivolumab (BMS936558) 218
8.4.12 GSK1572932A (MAGE-A3 Cancer Immunotherapeutic) 225
8.4.13 Halaven (eribulin mesylate) 230
9 Current and Future Players 234
9.1 Overview 234
9.2 Trends in Corporate Strategy 237
9.3 Company Profiles 238
9.3.1 Roche/Genentech 238
9.3.2 Pfizer 241
9.3.3 Bristol-Myers Squibb 243
9.3.4 Eli Lilly 245
9.3.5 Boehringer Ingelheim 248
9.3.6 Novartis 250
10 Market Outlook 251
10.1 Global Markets 251
10.1.1 Forecast 251
10.1.2 Drivers and Barriers - Global Issues 255
10.2 United States 258
10.2.1 Forecast 258
10.2.2 Key Events 261
10.2.3 Drivers and Barriers 262
10.3 France 265
10.3.1 Forecast 265

10.3.2 Key Events 268
10.3.3 Drivers and Barriers 269
10.4 Germany 271
10.4.1 Forecast 271
10.4.2 Key Events 274
10.4.3 Drivers and Barriers 275
10.5 Italy 277
10.5.1 Forecast 277
10.5.2 Key Events 280
10.5.3 Drivers and Barriers 281
10.6 Spain 283
10.6.1 Forecast 283
10.6.2 Key Events 285
10.6.3 Drivers and Barriers 286
10.7 United Kingdom 288
10.7.1 Forecast 288
10.7.2 Key Events 292
10.7.3 Drivers and Barriers 293
10.8 Japan 295
10.8.1 Forecast 295
10.8.2 Key Events 299

10.8.3 Drivers and Barriers 299
10.9 China 302
10.9.1 Forecast 302
10.9.2 Key Events 305
10.9.3 Drivers and Barriers 305
10.10 India 308
10.10.1 Forecast 308
10.10.2 Key Events 312
10.10.3 Drivers and Barriers 312
11 Appendix 314
11.1 Bibliography 314
11.2 Abbreviations 344
11.3 Methodology 349

11.4 Forecasting Methodology 349
11.4.1 Number of NSCLC Patients Currently Seeking Treatment 349
11.4.2 Percent Drug-treated Patients 350
11.4.3 Drugs Included in Each Therapeutic Class 350
11.4.4 Launch and Patent Expiry Dates 351
11.4.5 General Pricing Assumptions 352
11.4.6 Individual Drug Assumptions 355
11.4.7 Generic Erosion 366
11.4.8 Pricing of Pipeline Agents 366
11.5 Physicians and Specialists Included in This Study 369
11.6 Survey of Prescribing Physicians 371
11.7 About the Authors 372
11.7.1 Author 372
11.7.2 Epidemiologist 372
11.7.3 Global Head of Healthcare 373
11.8 About GlobalData 374
11.9 Disclaimer 374

List of Tables
Table 1: Symptoms of Disease NSCLC 31
Table 2: Risk Factors and Comorbidities for Lung Cancer 33
Table 3: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009 40
Table 4: 9MM, Sources of NSCLC Incidence Data 61
Table 5: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 69
Table 6: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012 72
Table 7: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N (Row %), 2012 73
Table 8: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, N (Row %), 2012 76
Table 9: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ?40 Years, Men and Women, N (Row %) , 2012 79
Table 10: Comparison of GlobalData Forecast for Lung Cancer Incident Cases with Globocan 2008 85
Table 11: Treatment Guidelines for NSCLC 86
Table 12: Stage Definitions for NSCLC 89
Table 13: Treatment Overview by Stage of Diagnosis for NSCLC 94
Table 14: Leading Treatments for NSCLC 116
Table 15: Product Profile - Alimta (pemetrexed disodium) 117
Table 16: Alimta SWOT Analysis, 2013 120
Table 17: Global Sales Forecasts ($m) for Alimta, 2012-2022 120
Table 18: Product Profile - Abraxane (nab-paclitaxel) 122
Table 19: Abraxane SWOT Analysis, 2013 124
Table 20: Global Sales Forecasts ($m) for Abraxane, 2012-2022 125
Table 21: Product Profile - Iressa (gefitinib) 127
Table 22: Iressa SWOT Analysis, 2013 129
Table 23: Global Sales Forecasts ($m) for Iressa, 2012-2022 130
Table 24: Product Profile - Tarceva (erlotinib hydrochloride) 131
Table 25: Tarceva SWOT Analysis, 2013 135

Table 26: Global Sales Forecasts ($m) for Tarceva, 2012-2022 136
Table 27: Product Profile - Xalkori (crizotinib) 137
Table 28: Xalkori SWOT Analysis, 2013 140
Table 29: Global Sales Forecasts ($m) for Xalkori, 2012-2022 141
Table 30: Product Profile - Avastin (bevacizumab) 142
Table 31: Avastin SWOT Analysis, 2013 144
Table 32: Global Sales Forecasts ($m) for Avastin, 2012-2022 145
Table 33: Overall Unmet Needs - Current Level of Attainment 147
Table 34: Clinical Unmet Needs - Gap Analysis, 2013 152
Table 35: NSCLC - Clinical Trials by Phase and Status, 2013 157
Table 36: Non-Small Cell Lung Cancer - Phase I-II Pipeline, 2013 158
Table 37: NSCLC - Phase III Pipeline, 2013 159
Table 38: NSCLC - Advantages and Disadvantages of Therapeutic Classes 159
Table 39: Product Profile - onartuzumab (MetMab) 161
Table 40: onartuzumab SWOT Analysis, 2013 166
Table 41: Global Sales Forecasts ($m) for onartuzumab, 2012-2022 167
Table 42: Product Profile - necitumumab (IMC-11F8) 168
Table 43: necitumumab SWOT Analysis, 2013 171
Table 44: Global Sales Forecasts ($m) for necitumumab, 2012-2022 172
Table 45: Product Profile - ramucirumab (IMC-1121B) 173
Table 46: ramucirumab SWOT Analysis, 2013 176
Table 47: Global Sales Forecasts ($m) for ramucirumab, 2012-2022 177
Table 48: Product Profile - custirsen (OGX-011) 179
Table 49: custirsen SWOT Analysis, 2013 182
Table 50: Global Sales Forecasts ($m) for custirsen, 2012-2022 184
Table 51: Product Profile - ganetespib (STA-9090) 185
Table 52: ganetespib SWOT Analysis, 2013 190
Table 53: Global Sales Forecasts ($m) for ganetespib, 2012-2022 191

Table 54: Product Profile - nintedanib (BIBF-1120) 192
Table 55: nintedanib SWOT Analysis, 2013 195
Table 56: Global Sales Forecasts ($m) for nintedanib, 2012-2022 196
Table 57: Product Profile - afatinib (BIBW-2992) 197
Table 58: afatinib SWOT Analysis, 2013 201
Table 59: Global Sales Forecasts ($m) for afatinib, 2012-2022 202
Table 60: Product Profile - dacomitinib (PF-00299804) 202
Table 61: dacomitinib SWOT Analysis, 2013 206
Table 62: Global Sales Forecasts ($m) for dacomitinib, 2012-2022 207
Table 63: Product Profile - LDK378 208
Table 64: LDK378 SWOT Analysis, 2013 211
Table 65: Global Sales Forecasts ($m) for LDK378, 2012-2022 213
Table 66: Product Profile - Yervoy (ipilimumab) 213
Table 67: Yervoy SWOT Analysis, 2013 216
Table 68: Global Sales Forecasts ($m) for Yervoy, 2012-2022 217
Table 69: Product Profile - nivolumab (BMS936558) 218
Table 70: nivolumab SWOT Analysis, 2013 223
Table 71: Global Sales Forecasts ($) for nivolumab, 2012-2022 224
Table 72: Product Profile - GSK1572932A (MAGE-A3 immunotherapy) 226
Table 73: MAGE-A3 (GSK1572932A ) SWOT Analysis, 2013 228
Table 74: Global Sales Forecasts ($m) for MAGE-A3, 2012-2022 229
Table 75: Product Profile - Halaven (eribulin mesylate) 230
Table 76: Halaven SWOT Analysis, 2013 233
Table 77: Global Sales Forecasts ($m) for Halaven, 2012-2022 234
Table 78: Key Companies in the NSCLC Market, 2013 236
Table 79: Roche/Genentech's NSCLC Portfolio Assessment, 2013 240
Table 80: Roche/Genentech SWOT Analysis, 2013 240
Table 81: Pfizer's NSCLC Portfolio Assessment, 2013 242

Table 82: Pfizer SWOT Analysis, 2013 242
Table 83: Bristol-Myers Squibb's NSCLC Portfolio Assessment, 2013 244
Table 84: BMS SWOT Analysis, 2013 245
Table 85: Eli Lilly's NSCLC Portfolio Assessment, 2013 247
Table 86: Eli Lilly SWOT Analysis, 2013 247
Table 87: Boehringer Ingelheim's NSCLC Portfolio Assessment, 2013 249
Table 88: BI SWOT Analysis, 2013 249
Table 89: Novartis NSCLC Portfolio Assessment, 2013 251
Table 90: Novartis SWOT Analysis, 2013 251
Table 91: Global Sales Forecasts ($m) for NSCLC, 2012-2022 253
Table 92: Global NSCLC Market - Drivers and Barriers, 2012-2022 255
Table 93: Sales Forecasts ($m) for NSCLC in the United States, 2012-2022 259
Table 94: Key Events Impacting Sales for NSCLC in the United States, 2012-2022 261
Table 95: NSCLC Market in the United States- Drivers and Barriers, 2012-2022 262
Table 96: Sales Forecasts ($m) for NSCLC in France, 2012-2022 267
Table 97: Key Events Impacting Sales for NSCLC in France, 2012-2022 268
Table 98: NSCLC Market in France - Drivers and Barriers, 2012-2022 269
Table 99: Sales Forecasts ($m) for NSCLC in Germany, 2012-2022 272
Table 100: Key Events Impacting Sales for NSCLC in Germany, 2012-2022 274
Table 101: NSCLC Market in Germany - Drivers and Barriers, 2012-2022 275
Table 102: Sales Forecasts ($m) for NSCLC in Italy, 2012-2022 278
Table 103: Key Events Impacting Sales for NSCLC in Italy, 2012-2022 280
Table 104: NSCLC Market in Italy - Drivers and Barriers, 2012-2022 281
Table 105: Sales Forecasts ($m) for NSCLC in Spain, 2012-2022 284
Table 106: Key Events Impacting Sales for NSCLC in Spain, 2012-2022 285
Table 107: NSCLC Market in Spain - Drivers and Barriers, 2012-2022 286
Table 108: Sales Forecasts ($m) for NSCLC in the UK, 2012-2022 289

Table 109: Key Events Impacting Sales for NSCLC in the UK, 2012-2022 292
Table 110: NSCLC Market in the United Kingdom - Drivers and Barriers, 2012-2022 293
Table 111: Sales Forecasts ($m) for NSCLC in Japan, 2012-2022 297
Table 112: Key Events Impacting Sales for NSCLC in Japan, 2012-2022 299
Table 113: NSCLC Market in Japan - Drivers and Barriers, 2012-2022 299
Table 114: Sales Forecasts ($m) for NSCLC in China, 2012-2022 303
Table 115: Key Events Impacting Sales for Disease NSCLC in China, 2012-2022 305
Table 116: NSCLC Market in China - Drivers and Barriers, 2012-2022 305
Table 117: Sales Forecasts ($m) for NSCLC in India, 2012-2022 310
Table 118: Key Events Impacting Sales for NSCLC in India, 2012-2022 312
Table 119: NSCLC Market in India - Drivers and Barriers, 2012-2022 312
Table 120: Five Year Prevalence 350
Table 121: Key Launch Dates 351
Table 122: Key Patent Expiries 352
Table 123: Physicians Surveyed by Country 371

1.2 List of Figures
Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ?40 Years, 1993-2002 39
Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ?40 Years, 1993-2002 39
Figure 3: Age-Standardized (US, 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999-2008 43
Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, US, 1993-2008 44
Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US 45
Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, France, 1993-2008 47
Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Germany, 1993-2008 48
Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Italy, 1993-2008 50
Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Spain, 1991-2008 52
Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ?40 Years, UK, 1993-2008 53

Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Japan, 1993-2008 55
Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, China, 1993-2008 57
Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ?40 Years, India, 1993-2002 59
Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012-2022 71
Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N, 2012 74
Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012 75

Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, % and N, 2012 78
Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ?40 Years, %, 2012 81
Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases Ages >40 Years and the General Population, Men and Women, %, 2012 82
Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ?40 Years, N, 2012 83
Figure 21: NSCLC Therapeutics - Clinical Trials by Country, 2013 156
Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012-2022 160
Figure 23: Company Portfolio Gap Analysis in NSCLC, 2012-2022 236
Figure 24: Global Sales for NSCLC by Region, 2012-2022 254
Figure 25: Sales for NSCLC in the United States by Drug Class, 2012-2022 261
Figure 26: Sales for NSCLC in France by Drug Class, 2012-2022 268
Figure 27: Sales for NSCLC in Germany by Drug Class, 2012-2022 274
Figure 28: Sales for NSCLC in Italy by Drug Class, 2012-2022 280
Figure 29: Sales for NSCLC in Spain by Drug Class, 2012-2022 285
Figure 30: Sales for NSCLC in the United Kingdom by Drug Class, 2012-2022 291
Figure 31: Sales for NSCLC in Japan by Drug Class, 2012-2022 298
Figure 32: Sales for NSCLC in China by Drug Class, 2012-2022 304
Figure 33: Sales for NSCLC in India by Drug Class, 2012-2022 311

To order this report: PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p02029815/PharmaPoint-Non-Small-Cell-Lung-Cancer---Global-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArcho...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize supplier management. Learn about enterprise architecture strategies for designing connected systems tha...
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how thes...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) ir...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn rea...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder ...
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other mach...
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice s...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example...